Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.
Does carriage of a reduced-function CYP2C19 allele increase the risk of major adverse cardiovascular events in patients treated with clopidogrel for PCI?
Patients treated with clopidogrel predominantly for percutaneous coronary intervention (PCI)
Carriage of at least 1 reduced-function CYP2C19 allele
Major adverse cardiovascular events, particularly stent thrombosishard clinical
Carriage of a reduced-function CYP2C19 allele significantly increases the risk of MACE and stent thrombosis in patients receiving clopidogrel for PCI.
Absolute Event Rate: 0% vs 0%
Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jessica L. Mega
General Cardiology
Tabassome Simon
Preventive Cardiology
Jean‐Philippe Collet
Université Claude Bernard Lyon 1
JAMA
Harvard University
Brigham and Women's Hospital
Harvard University Press
Building similarity graph...
Analyzing shared references across papers
Loading...
Mega et al. (Tue,) reported a other. Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.
synapsesocial.com/papers/697b9d0ab1eeb5d474b354a4 — DOI: https://doi.org/10.1001/jama.2010.1543